Loading cancer entity…
Loading cancer entity…
Clinical trials
10,628 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,642)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07285174 | Shanghai Lymphoma Clinical Cohort | not yet recruiting | — | 1,000 | Ruijin HospitalOTHER | 0 | Dec 16, 2025 | clinicaltrials |
| NCT07286539 | Precision Physical Exercise for Personalized Onco-Hematology.(PEPOH) | not yet recruiting | N/A | 150 | University of SalamancaOTHER | 0 | Dec 16, 2025 | clinicaltrials |
| NCT07279584 |
| Golidocitinib Combined With GemOx in RR PTCL |
| not yet recruiting |
| Phase 2 |
| 31 |
| Ruijin HospitalOTHER |
| 0 |
| Dec 12, 2025 |
| clinicaltrials |
| NCT07276698 | Clinical Study on Maintenance Therapy With Selinexor Combined With Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for NK/T-cell Lymphoma | not yet recruiting | Phase 2 | 39 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Dec 11, 2025 | clinicaltrials |
| NCT07276737 | Preconditioning With a Combination of Thiotepa, Cyclophosphamide, and Busulfan for Allogeneic Hematopoietic Stem Cell Transplantation in the Treatment of NK/T-Cell Lymphoma | not yet recruiting | Phase 2 | 37 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Dec 11, 2025 | clinicaltrials |
| NCT07264894 | ZSDT for the Treatment of R/R Mantle Cell Lymphoma After BTK Inhibitor Failure: a Multi-center Prospective Clinical Trial | not yet recruiting | Phase 4 | 30 | Zhengzhou UniversityOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT07259122 | A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström Macroglobulinemia(ZBR in WM) | not yet recruiting | Phase 2 | 43 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07259941 | PET-CT in Lymphoma Among the Eldery | not yet recruiting | — | 63 | Assiut UniversityOTHER | 0 | Dec 2, 2025 | clinicaltrials |
| NCT07253103 | Effects of a Resistance Physical Exercise Program in Multiple Myeloma Patients | not yet recruiting | N/A | 50 | University of SalamancaOTHER | 0 | Nov 28, 2025 | clinicaltrials |
| NCT06547866 | Study Evaluating the Efficacy and Tolerance of a Zanubrutinib and BGB-11417 Combination in Patients Previously Treated for Waldenström Macroglobulinemia(WAZABI) | not yet recruiting | Phase 2 | 102 | French Innovative Leukemia OrganisationOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07213882 | A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)(CITY) | not yet recruiting | Early Phase 1 | 30 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Oct 9, 2025 | clinicaltrials |
| NCT07210749 | Radiotherapy 12Gy in 6 Fractions For Orbital Lymphoma | not yet recruiting | N/A | 36 | British Columbia Cancer AgencyOTHER | 1 | Oct 7, 2025 | clinicaltrials |
| NCT07207785 | PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma(FIL_PUMA) | not yet recruiting | Phase 2 | 56 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT07209163 | Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 48 | Ruijin HospitalOTHER | 0 | Oct 6, 2025 | clinicaltrials |
| NCT07206264 | Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment(ADAPT-MCL) | not yet recruiting | Phase 2 | 45 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT06925555 | Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS | not yet recruiting | Phase 2 | 25 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT07198464 | Relmacabtagene Autoleucel Combined With Autologous Hematopoietic Stem Cell Transplantation, Orelabrutinib, and Sintilimab for Primary Central Nervous System Lymphoma | not yet recruiting | N/A | 30 | Zhengzhou UniversityOTHER | 0 | Sep 30, 2025 | clinicaltrials |
| NCT06979076 | A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL | not yet recruiting | Phase 1 / Phase 2 | 12 | MingSight Pharmaceuticals, IncINDUSTRY | 0 | Sep 29, 2025 | clinicaltrials |
| NCT07187960 | Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma | not yet recruiting | Phase 3 | 228 | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.INDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT07185477 | A Single-arm Single-center Trial of Bridging GPRC5D/CD3 Bispecific Antibody Treatment With BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma(QLS32015) | not yet recruiting | Early Phase 1 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Sep 22, 2025 | clinicaltrials |
| NCT07181239 | Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients | not yet recruiting | Phase 3 | 280 | Keymed Biosciences Co.LtdINDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT07107204 | A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies | not yet recruiting | Phase 1 / Phase 2 | 116 | Biotroy TherapeuticsINDUSTRY | 0 | Sep 17, 2025 | clinicaltrials |
| NCT07168291 | Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma | not yet recruiting | Early Phase 1 | 3 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Sep 17, 2025 | clinicaltrials |
| NCT07178457 | Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant Maintenance(BeCALM) | not yet recruiting | Phase 3 | 84 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Sep 17, 2025 | clinicaltrials |
| NCT07045168 | Risk-adapted Therapeutic Strategy in +1q NDMM | not yet recruiting | — | 200 | FengYan JinOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT07169565 | Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia | not yet recruiting | Phase 1 | 21 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Sep 11, 2025 | clinicaltrials |
| NCT07159906 | Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 62 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT07157579 | Notch 1 Mutation in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patient | not yet recruiting | — | 80 | Sohag UniversityOTHER | 0 | Sep 5, 2025 | clinicaltrials |
| NCT07144657 | Prospective Study of Frontline Antibiotics Therapy in the Treatment of Early-stage HP-negative Gastric MALT Lymphoma(GastricMALToma) | not yet recruiting | Phase 2 | 40 | National Taiwan University HospitalOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT07139353 | Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 54 | Sun Yat-sen UniversityOTHER | 0 | Aug 24, 2025 | clinicaltrials |
| NCT07035379 | A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL | not yet recruiting | Phase 1 / Phase 2 | 66 | Zhejiang Teruisi Pharmaceutical Inc.INDUSTRY | 1 | Aug 22, 2025 | clinicaltrials |
| NCT07131449 | Serum Histone Succinylation as a Novel Prognostic Biomarker in Hematological Malignancies(succinylation) | not yet recruiting | — | 200 | The First Affiliated Hospital of Xinxiang Medical CollegeOTHER | 0 | Aug 20, 2025 | clinicaltrials |
| NCT05779930 | Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL | not yet recruiting | Early Phase 1 | 12 | Nationwide Children's HospitalOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT06665217 | G-Pola-ZLP in Diffuse Large B-Cell Lymphoma | not yet recruiting | Phase 2 | 80 | Navy General Hospital, BeijingOTHER | 0 | Aug 14, 2025 | clinicaltrials |
| NCT07113496 | RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies | not yet recruiting | Phase 1 | 27 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 13, 2025 | clinicaltrials |
| NCT07117305 | CD7 CAR-T Combined With Autologous Hematopoietic Stem Cell Transplantation | not yet recruiting | Phase 1 / Phase 2 | 38 | Zhengzhou UniversityOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT07114432 | RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma | not yet recruiting | Phase 1 | 19 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT07090954 | A Study of GR1803 Injection in Combination With Anti-CD38 Monoclonal Antibody for the Treatment of Participants With Multiple Myeloma | not yet recruiting | Phase 1 / Phase 2 | 32 | Genrix (Shanghai) Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 29, 2025 | clinicaltrials |
| NCT07081607 | Golidocitinib With Azacitidine and Chidamide in Patients With Peripheral T-cell Lymphoma. | not yet recruiting | Phase 2 | 30 | Ruijin HospitalOTHER | 0 | Jul 23, 2025 | clinicaltrials |
| NCT06580223 | Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma | not yet recruiting | Phase 3 | 530 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT07070934 | CAR-T vs. Auto-SCT: Which Works Better for New Myeloma Patients?(ASCTvsCAR-T) | not yet recruiting | Phase 2 | 60 | Xuzhou Medical UniversityOTHER | 0 | Jul 17, 2025 | clinicaltrials |
| NCT07070960 | A Study of Anti-BCMA CAR-T Therapy in Newly Diagnosed Myeloma Patients Who Are Transplant-ineligible(CAR-T) | not yet recruiting | N/A | 35 | Xuzhou Medical UniversityOTHER | 0 | Jul 17, 2025 | clinicaltrials |
| NCT07068906 | A Clinical Study Exploring CT1194C in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | not yet recruiting | Phase 1 | 27 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT07055724 | Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis | not yet recruiting | Phase 2 | 17 | Nanjing IASO Biotechnology Co., Ltd.INDUSTRY | 0 | Jul 9, 2025 | clinicaltrials |
| NCT06385522 | A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System | not yet recruiting | Phase 1 | 37 | Boston Immune Technologies and TherapeuticsINDUSTRY | 0 | Jul 8, 2025 | clinicaltrials |
| NCT07046663 | Long-term Assessment of Chlormethine Gel in Mycosis Fungoides(FIL_CLOR-CTCL) | not yet recruiting | — | 190 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT07034755 | Phase II Clinical Study on the Safety and Efficacy of Combined CAR-T Therapy Following Autologous Stem Cell Transplantation in Multiple Myeloma | not yet recruiting | N/A | 20 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT06720207 | Efficacy of 68Ga-Pentixafor PET/MR in Detecting Non-Hodgkin Lymphoma and Multiple Myeloma Lesions | not yet recruiting | — | 30 | Shanghai East HospitalOTHER | 0 | Jun 27, 2025 | clinicaltrials |
| NCT07032532 | Assessing An Oral JAK1 Inhibitor, Golidocitinib, in Patients Who Have Newly Diagnosed Peripheral T-Cell Lymphoma (JACKPOT23) | not yet recruiting | Phase 2 | 35 | Sun Yat-sen UniversityOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT07032324 | A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG1101 )(CT1190B) | not yet recruiting | Phase 1 | 27 | Qian WenbinOTHER | 1 | Jun 23, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Dec 16, 2025source: clinicaltrials